Tybourne Capital Management (Hk) LTD Bicycle Therapeutics PLC Transaction History

Tybourne Capital Management (Hk) LTD

$398 Million
Q2 2024

A detailed history of Tybourne Capital Management (Hk) LTD transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Tybourne Capital Management (Hk) LTD holds 1,509,713 shares of BCYC stock, worth $35.4 Million. This represents 7.67% of its overall portfolio holdings.

Number of Shares

1,509,713

Previous 1,545,026 2.29%

Holding current value

$35.4 Million

Previous $38.5 Million 20.57%

% of portfolio

7.67%

Previous 8.61%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.02 - $24.69 $706,966 - $871,877	-35,313 Reduced 2.29%	1,509,713 $30.6 Million
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $1.76 Million - $2.75 Million	-105,294 Reduced 6.38%	1,545,026 $38.5 Million
Q4 2023 Feb 14, 2024	BUY	$13.29 - $22.2 $4.9 Million - $8.18 Million	368,500 Added 28.75%	1,650,320 $29.8 Million
Q2 2023 Aug 14, 2023	SELL	$18.95 - $28.67 $2.41 Million - $3.64 Million	-127,011 Reduced 9.02%	1,281,820 $32.7 Million
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $10.1 Million - $15.8 Million	503,109 Added 55.55%	1,408,831 $30 Million
Q4 2022 Feb 14, 2023	SELL	$20.37 - $32.9 $2.76 Million - $4.46 Million	-135,609 Reduced 13.02%	905,722 $26.8 Million
Q3 2022 Nov 14, 2022	SELL	$17.49 - $28.44 $1.97 Million - $3.21 Million	-112,795 Reduced 9.77%	1,041,331 $24.2 Million
Q1 2022 May 04, 2022	SELL	$40.12 - $59.5 $36.1 Million - $53.5 Million	-899,678 Reduced 43.81%	1,154,126 $50.6 Million
Q4 2021 Jan 26, 2022	BUY	$41.7 - $61.14 $4 Million - $5.86 Million	95,843 Added 4.9%	2,053,804 $125 Million
Q2 2019 Aug 14, 2019	BUY	$10.06 - $14.63 $19.7 Million - $28.6 Million	1,957,961 New	1,957,961 $19.7 Million

Others Institutions Holding BCYC

# of Institutions

111

Shares Held

41M

Call Options Held

3.4K

Put Options Held

12.4K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $696M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tybourne Capital Management (Hk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tybourne Capital Management (Hk) LTD with notifications on news.

Account

Tybourne Capital Management (Hk) LTD Bicycle Therapeutics PLC Transaction History